EGFR and colorectal carcinoma: The varied response rates to EGFR-targeted treatment in patients with colorectal cancer (CRC) are explained by the significant intra- and inter-patient heterogeneity in mutant EGFR expression, as well as that of additional genetic changes linked to EGFR inhibition, such as KRAS and PIK3CA mutations [69].